ART101 in Patients With Hypertension

Phase 1, open-label trial of ART101 in hypertension (HTN) (2 arms), sponsored by Arnatar Therapeutics. Primary endpoints: Incidence of adverse events, adverse events of special interest and SAEs at Day 169 and Number of participants with abnormal laboratory values and/or adverse events that are related to treatment at Day 169. Started Oct 2025; status: active, not recruiting.